Toxicity and compliance with a chemoradiotherapy schedule for advanced nasopharyngeal carcinoma: A single institution experience using the Intergroup 0099 study regimen [2]

Acta Oncologica

Volumn 44, Issue 1, 2005, Pages 85-86

  Chajón, Enrique A ^a   García Berrocal, Maria Isabel ^a   De La Fuente, Cristina ^a   Regueiro, Carlos A ^a   Romero, Jesús ^a   Valcárcel, Francisco ^a   Magallón, Rosa ^a   Hernanz, Raúl ^a   De La Torre, Alejandro ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ADVANCED CANCER; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CHOICE; FEBRILE NEUTROPENIA; HUMAN; KIDNEY FAILURE; LETTER; LEUKOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NASOPHARYNX CARCINOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APPOINTMENTS AND SCHEDULES; CLINICAL TRIALS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT COMPLIANCE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 13844275547     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860510007459     Document Type: Letter

References (8)

1. Al-Sarraf M, LeBlanc M, Shanker Giri, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-17.
2. Bahl M, Siu L, Pond G, et al. Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. 2004 ASCO Annual Meeting, Abstract No. 5572.
3. Lee AW, Lau WH, Tung SY, et al. Prospective randomized study on therapeutic gain achieved by addition of chemotherapy for T1-4N2-3M0 nasopharyngeal carcinoma (NPC). 2004 ASCO Annual Meeting, Abstract No. 5506.
4. Thephamongkhol K, Zhou J, Browman G, et al. Chemoradiotherapy versus radiotherapy alone for nasopharyngeal carcinoma: A meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases. 2004 ASCO Annual Meeting, Abstract No. 5522.
5. Langendijk JA, Leemans R, Buter J, et al. A meta-analysis of the addition of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma. ASTRO 2003, Abstract No. 200.
6. Thephamongkhol K, Browman G, Hodson I, et al. Does the addition of chemotherapy to radiotherapy improve the survival of patients with locally advanced nasopharyngeal cancer? A systematic review and meta-analysis of randomized controlled trials. ASTRO 2003, Abstract No. 201.
7. Chan ATC, Teo PML, Ngan RKC, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002;20:2038-44.
8. Jin-Ching Lin, Jian-Sheng Jan, Chen-Yi Hsu, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: Positive effect on overall survival and progression-free survival. J Clin Oncol 2003;21:631-7.